The pharmaceutical industry’s revenues rose by just 3 percent in 2020, down from an average of 11.8 percent in the previous five years.
But it was a notable year for mergers and acquisitions. According to analysts at SSI Securities, the total value of M&A was VND1.68 trillion ($73 million) last year and involved a number of foreign investors.
In May, South Korean conglomerate SK Group, which makes anti-cancer and cardiovascular drugs and mental health medications, paid VND920 billion to acquire a 25 percent stake in Imexpharm Pharmaceutical Joint Stock Company.
In August, Japan’s Aska Pharmaceutical acquired a 24.9 percent stake in Ha Tay Pharmaceutical Joint Stock Company (Hataphar).
In December, German generic drugmaker Stada paid VND400 billion to increase its stake in Pymepharco by 6 percent to nearly 76 percent.
SSI analysts estimated the pharmaceutical industry to grow by 15 percent in 2021 mainly due to a rapidly aging population and rising incomes.
